0001502152 2021-10-01 2022-09-30 0001502152 2022-03-31 0001502152 2023-01-03 0001502152 2022-09-30 0001502152 2021-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesCPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesCPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2021-09-30 0001502152 2020-10-01 2021-09-30 0001502152 2020-09-30 0001502152 us-gaap:CommonStockMember 2020-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2020-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2020-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2020-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2020-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001502152 gstc:StockPayableMember 2020-09-30 0001502152 us-gaap:RetainedEarningsMember 2020-09-30 0001502152 us-gaap:CommonStockMember 2021-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001502152 gstc:StockPayableMember 2021-09-30 0001502152 us-gaap:RetainedEarningsMember 2021-09-30 0001502152 us-gaap:CommonStockMember 2020-10-01 2021-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2020-10-01 2021-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2020-10-01 2021-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2020-10-01 2021-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2020-10-01 2021-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-09-30 0001502152 gstc:StockPayableMember 2020-10-01 2021-09-30 0001502152 us-gaap:RetainedEarningsMember 2020-10-01 2021-09-30 0001502152 us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-09-30 0001502152 gstc:StockPayableMember 2021-10-01 2022-09-30 0001502152 us-gaap:RetainedEarningsMember 2021-10-01 2022-09-30 0001502152 us-gaap:CommonStockMember 2022-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001502152 gstc:StockPayableMember 2022-09-30 0001502152 us-gaap:RetainedEarningsMember 2022-09-30 0001502152 srt:OfficerMember 2022-09-30 0001502152 srt:OfficerMember 2021-09-30 0001502152 srt:ChiefFinancialOfficerMember 2022-09-30 0001502152 srt:ChiefExecutiveOfficerMember 2022-09-30 0001502152 srt:BoardOfDirectorsChairmanMember gstc:MrKatzaroffMember 2022-02-01 2022-02-28 0001502152 srt:BoardOfDirectorsChairmanMember gstc:MrKatzaroffMember 2022-09-30 0001502152 srt:BoardOfDirectorsChairmanMember gstc:MrKatzaroffMember 2021-10-01 2022-09-30 0001502152 gstc:MrKatzaroffMember 2021-10-01 2022-09-30 0001502152 srt:ChiefExecutiveOfficerMember gstc:SydneyJimMember 2021-01-31 0001502152 srt:ChiefExecutiveOfficerMember gstc:MsBlankenshipMember 2021-03-31 0001502152 srt:ChiefExecutiveOfficerMember gstc:MsBlankenshipMember 2021-03-01 2021-03-31 0001502152 srt:ChiefExecutiveOfficerMember gstc:MsBlankenshipMember 2021-09-30 0001502152 gstc:MsBlankenshipMember 2021-09-30 0001502152 gstc:MsBlankenshipMember 2020-10-01 2021-09-30 0001502152 gstc:MsBlankenshipMember us-gaap:SeriesEPreferredStockMember 2020-10-01 2021-09-30 0001502152 srt:ChiefExecutiveOfficerMember gstc:JamesKatzaroffMember 2020-10-01 2021-09-30 0001502152 srt:ChiefFinancialOfficerMember gstc:RobertChicoskiMember 2021-09-30 0001502152 gstc:ConvertibleNoteDateApril132017Member 2021-10-01 2022-09-30 0001502152 gstc:ConvertibleNoteDateApril132017Member 2022-09-30 0001502152 gstc:ConvertibleNoteDateApril132017Member 2021-09-30 0001502152 us-gaap:ConvertibleDebtMember 2021-10-01 2022-09-30 0001502152 us-gaap:ConvertibleDebtMember 2022-09-30 0001502152 us-gaap:ConvertibleDebtMember 2021-09-30 0001502152 us-gaap:ConvertibleDebtMember 2020-10-01 2021-09-30 0001502152 gstc:ConvertibleDebtOneMember 2021-09-30 0001502152 gstc:AdvanceMember 2022-09-30 0001502152 gstc:AdvanceMember 2021-09-30 0001502152 us-gaap:SeriesBPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesCPreferredStockMember 2017-09-12 0001502152 us-gaap:SeriesDPreferredStockMember 2017-09-21 0001502152 us-gaap:SeriesDPreferredStockMember 2017-09-20 2017-09-21 0001502152 us-gaap:SeriesEPreferredStockMember 2015-08-03 0001502152 us-gaap:SeriesEPreferredStockMember 2015-08-02 2015-08-03 0001502152 srt:DirectorMember us-gaap:SeriesEPreferredStockMember 2022-09-30 0001502152 srt:DirectorMember us-gaap:SeriesEPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2017-09-21 0001502152 us-gaap:SeriesFPreferredStockMember 2017-09-20 2017-09-21 0001502152 gstc:ConvertibleDebtOneMember 2020-10-01 2021-09-30 0001502152 srt:ChiefFinancialOfficerMember 2021-09-30 0001502152 us-gaap:WarrantMember 2021-10-01 2022-09-30 0001502152 srt:ChiefExecutiveOfficerMember 2021-10-01 2022-09-30 0001502152 2021-12-31 0001502152 us-gaap:CashMember 2022-09-30 0001502152 us-gaap:WarrantMember 2020-10-01 2021-09-30 0001502152 srt:MinimumMember 2021-10-01 2022-09-30 0001502152 2021-10-01 2022-03-31 0001502152 gstc:CommonStockWarrantsMember 2022-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2021-08-11 0001502152 us-gaap:SeriesGPreferredStockMember 2021-08-09 2021-08-11 0001502152 us-gaap:SeriesGPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2021-08-10 2021-08-11 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001502152 2022-02-26 2022-02-28 0001502152 us-gaap:WarrantMember 2022-09-30 0001502152 us-gaap:WarrantMember 2021-10-01 2022-06-30 0001502152 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2022-06-30 0001502152 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2022-06-30 0001502152 gstc:MeasurementDividendYieldRateMember us-gaap:WarrantMember 2022-06-30 0001502152 2022-06-30 0001502152 us-gaap:PatentsMember gstc:FabrizioDeSilvestriMember gstc:LicenseAgreementMember 2020-08-22 2020-08-23 0001502152 us-gaap:PatentsMember gstc:LicenseAgreementMember 2020-08-22 2020-08-23 0001502152 2021-08-22 2021-08-23 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:SubsequentEventMember 2022-10-02 2022-10-03 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:SubsequentEventMember 2022-10-12 2022-10-13 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:SubsequentEventMember 2022-10-17 2022-10-18 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:SubsequentEventMember 2022-11-09 2022-11-10 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:SubsequentEventMember 2022-11-13 2022-11-14 iso4217:USD shares iso4217:USD shares pure 0001502152 false FY --09-30 2022

Unlimited

-1487810

1094560

-18504776

P3Y

P5Y

P2Y11M26D

P3Y4M17D

P1Y10M10D

P5Y

10-K true 2022-09-30 false 333-170315 GlobeStar Therapeutics Corporation WY 27-3480481 719 Jadwin Avenue Richland WA 99352 206 451-1970 Common stock, $0.001 par value No No Yes Yes Non-accelerated Filer false true false false 3963984 770360616 2738 M&K CPAS, PLLC Houston, Texas

6365

5960

3550

9915

5960

9915

5960

380735

222778

379126

119655

59650

20000

12581 21575 126294 86130

226270

223568

1204475

731781

1204475

731781

0.001

722326669

561495726

722325

561494

20000000

0.001

509988

510

0.001

1000000

1000

0.001

128991

386975

129

387

16581252

15228254

1515152 25980000 5000 499500

-18504776

-17016966

-1194560

-725821

9915

5960

2412

-2412

1265065

9091817

1265065

9091817

-1265065

-9094229

-146460 -419900 -5939

70346

287499

-222745

-707399

-1487810

-9801628

-0.00 -0.02 628539782 482090099

436218342

436217

509988

510

1000000

1000

386975

387

6118002

-7215338

-659222

40817050

40817

250685

291502

73260334

68260

7987737

8055997

5000000

5000

70000

75000

379500

120000 120000 11200000

11200

538700

549900

225000

38130 38130

-9801628

561495726

561494

509988

510

1000000

1000

386975

387

15228254

499500

-17016966

-725821

25798400

25798

-258

-25540

5000

19980000

19980

479520

-499500

6000000

6000

155460

161460

322266

186926

109052543

109053

234366

343419

-1487810

722326669

722325

509988

510

1000000

1000

128991

129

16581252

5000

-18504776

-1194560

-1487810

-9801628

322266

8055997

186926 75000

1275

54664

274803

2412

-146460

-419900

-5939

3550

-4783

172957

89313

259471

114217

15682

12696

-326995

-751232

95000

310000 81250

28900

16500

5000

499500

327400

675750

405

-75482

5960

81442

6365

5960

291500

25798 324500 499500 15000

225000

38130

Note 1. General Organization and Business GlobeStar Therapeutics Corporation (the “Company”) was incorporated on April 29, 2016. The Company’s year-end is September 30. On October 4, 2019, the Company filed Articles of Continuance with the Secretary of State of Wyoming to continue its business in the state of Wyoming. As part of these Articles of Continuance, effective October 4, 2019, the Company has no limit on the authorized shares of common stock that can be issued. The Company filed its Certificate of Dissolution with the Secretary of State of Nevada on October 21, 2019 because it is no longer a Nevada corporation. The Company is developing an expanded platform of products that include addition of treatment for Multiple Sclerosis and other neurodegenerative diseases. The potential pharmaceutical products related to treatment for multiple sclerosis are licensed to the Company through the worldwide licensing agreement described in Note 8.

Note 2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 7%">Level 1 -</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 93%">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Level 2 -</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Level 3 -</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs that are both significant to the fair value measurement and unobservable.</td></tr> </table> Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable and accrued expenses. Revenue Recognition The Company recognized revenue from product sales of its previous business upon product delivery. All of our products are shipped through a third-party fulfillment center to the customer and the customer takes title to product and assumes risk and ownership of the product when it is delivered. Shipping charges to customers and sales taxes collectible from customers, if any, are included in revenues. Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied. Advertising and Marketing Costs We expense advertising and marketing costs as incurred. Advertising and marketing costs were $43,031 and $119,125 for the years ended September 30, 2022 and 2021, respectively. Research and Development Costs Research and development costs are expensed as incurred. The Company incurred no research and development costs during the years ended September 30, 2022 and 2021. Cash and Cash Equivalents All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $6,365 and $5,960 as of September 30, 2022 and 2021, respectively. There were no cash equivalents as of September 30, 2022 and 2021. Property and equipment Property and equipment of the Company is stated at cost. In accordance with ASC Topic 360 Property, Plant and Equipment, expenditure for fixed assets that substantially increase the useful lives of existing assets are capitalized at cost and depreciated. Routine expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided principally on the straight-line method over the estimated useful lives of the asset. Depreciation expense was $0 during the year ended September 30, 2022 compared to $1,275 during the year ended September 30, 2021. Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of September 30, 2022 and 2021. <p id="xdx_847_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zfqSG7t6PLaf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Commitments and Contingencies The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of September 30, 2022 or 2021. <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ze6xt8BVSang" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Recently Issued Accounting Pronouncements Accounting standards promulgated by the Financial Accounting Standards Board (the “FASB”) are subject to change. Changes in such standards may have an impact on our future financial statements. The following are a summary of recent accounting developments. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.

Basis of Presentation The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.

Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 7%">Level 1 -</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 93%">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Level 2 -</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Level 3 -</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs that are both significant to the fair value measurement and unobservable.</td></tr> </table> Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable and accrued expenses.

Revenue Recognition The Company recognized revenue from product sales of its previous business upon product delivery. All of our products are shipped through a third-party fulfillment center to the customer and the customer takes title to product and assumes risk and ownership of the product when it is delivered. Shipping charges to customers and sales taxes collectible from customers, if any, are included in revenues. Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.

Advertising and Marketing Costs We expense advertising and marketing costs as incurred. Advertising and marketing costs were $43,031 and $119,125 for the years ended September 30, 2022 and 2021, respectively.

43031

119125

Research and Development Costs Research and development costs are expensed as incurred. The Company incurred no research and development costs during the years ended September 30, 2022 and 2021.

Cash and Cash Equivalents All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $6,365 and $5,960 as of September 30, 2022 and 2021, respectively. There were no cash equivalents as of September 30, 2022 and 2021.

6365

5960

Property and equipment Property and equipment of the Company is stated at cost. In accordance with ASC Topic 360 Property, Plant and Equipment, expenditure for fixed assets that substantially increase the useful lives of existing assets are capitalized at cost and depreciated. Routine expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided principally on the straight-line method over the estimated useful lives of the asset. Depreciation expense was $0 during the year ended September 30, 2022 compared to $1,275 during the year ended September 30, 2021.

1275

Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of September 30, 2022 and 2021.

<p id="xdx_847_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zfqSG7t6PLaf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Commitments and Contingencies The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of September 30, 2022 or 2021.

<p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ze6xt8BVSang" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Recently Issued Accounting Pronouncements Accounting standards promulgated by the Financial Accounting Standards Board (the “FASB”) are subject to change. Changes in such standards may have an impact on our future financial statements. The following are a summary of recent accounting developments. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.

Note 3. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the year ended September 30, 2022, the Company had a net loss of $1,487,810. As of September 30, 2022, the Company had a working capital deficit of $1,194,560 and an accumulated deficit of $18,504,776. The Company has minimal revenue. Without additional capital, the Company will not be able to remain in business. These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Management has plans to address the Company’s financial situation as follows: In the near term, management plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern. In the long term, management believes that the Company’s projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company’s future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.

<p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z4zwbbiZLRr6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Note 4. Related Party Transactions For the year ended September 30, 2022 As of September 30, 2022 and 2021, the Company owed $379,126 and $119,655 to officers of the Company for compensation which are recorded as accounts payable related party. Additionally, the Company received short term, unsecured, non-interest bearing advances from the Company’s CEO and CFO totaling $<span id="xdx_90D_eus-gaap--AccruedSalariesCurrent_iI_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z9ESsAISsBXg" title="Compensation">28,900 and repaid $<span id="xdx_907_eus-gaap--AccruedSalariesCurrent_iI_c20220930__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zfQZxf9nqWUa" title="Compensation">16,500. As of September 30, 2022, the Company owed $12,400 on these related party advances. In February 2022, the Company entered into an amended and restatement employment agreement with Jim Katzaroff, the CEO. Mr. Katzaroff is entitled to an annual salary of $<span id="xdx_902_eus-gaap--ProfessionalFees_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zjARpjX4P359" title="Annual fees">180,000 and a bonus as determined by the Board of Directors. Mr. Katzaroff may elect to receive payment in shares of stock based on the average of the three lowest trading prices for the 15 days prior to election of payment in stock. Further, in the event of a change of control of the Company, Mr. Katzaroff is entitled to a payment equal to 2.99 multiplied by the larger of the total compensation paid to Mr. Katzaroff over the prior 12-month period or the average compensation paid or payable to the Consultant over the prior <span id="xdx_906_ecustom--PayableToConsultantTerm_dxL_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zjg4ZTRWpG6k" title="Payable to consultant term::XDX::P3Y">three years. The Company awarded Mr. Katzaroff a total of <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zW4qJlJcc11" title="Common stock, shares outstanding">35,000,000 common stock options with an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z6w1wX74CIQc" title="Exercise price, per shares">0.009 per share, an exercise term of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20211001__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zk1JEDWxX1M5" title="Exercise term::XDX::P5Y">five years. <span id="xdx_900_ecustom--DescriptionOfOptions_c20211001__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z5ROpySVQaE7" title="Description of options">The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an equal amount of options as those instruments that are issued. The exercise price of these additional options will be 110% of the price per equity equivalent. The total fair value of these option grants at issuance was $284,840. During the year ended September 30, 2022, the Company recognized $186,926 of stock-based compensation, related to outstanding stock options. At September 30, 2022, the Company had $97,914 of unrecognized expenses related to options. <span id="xdx_903_ecustom--DescriptionOfAdditionalOptions_c20211001__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_ziUoMeugBUKh" title="Description of additional options">Additionally, Mr. Katzaroff will earn a fee related to an strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold. As of September 30, 2022, no amounts have been earned or paid. Mr. Katzroff will also receive an activity fee of 3% of gross revenues related to activities including securing a variety of vendor, sales or advertising relationships, or any new revenue generating activity. If such activity is a cost saving initiative instead of revenue generating, Mr. Katzaroff will receive 10% of the cost savings. As of September 30, 2022, no amounts have been earned or paid. For the year ended September 30, 2021 In January 2021, the Company’s former Chief Executive Officer Sydney Jim agreed to forgive all accrued but unpaid compensation of $<span id="xdx_908_eus-gaap--AccruedSalariesCurrent_iI_c20210131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SydneyJimMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zNQVnL8RC8na" title="Compensation">38,130, resulting in a gain on settlement of liabilities to the Company that was recorded to additional paid in capital. In March 2021, the Company entered into severance agreement with its former CEO Alex Blankenship. The Company owed Ms. Blankenship unpaid compensation of $<span id="xdx_906_eus-gaap--AccruedSalariesCurrent_iI_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBlankenshipMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z3UtLtU61BKl" title="Unpaid compensation">130,000 and agreed to issue <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBlankenshipMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zz2hcSU4ohgf" title="Issuance of common stock">8,600,000 shares of common stock in full settlement of this amount and release from the employment agreement with her. The shares had a fair value of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBlankenshipMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zGewsCLUEcqi" title="Fair value">447,200 based on the stock price at the date of the agreement. The Company recognized a loss on settlement of $<span id="xdx_90C_eus-gaap--GainLossRelatedToLitigationSettlement_c20210301__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBlankenshipMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zn8CkIfjCe4j" title="Loss on settlement">317,200 in connection with this agreement. The Company also issued an additional <span id="xdx_90D_eus-gaap--SharesIssued_iI_pid_uShares_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBlankenshipMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJfFQJATnO1e" title="Share issued">2,600,000 shares to Ms. Blankenship with a fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBlankenshipMember_zsorMzkSrGT9" title="Fair value">102,700 in connection with this agreement, which were included in the loss on settlement total of $<span id="xdx_901_eus-gaap--GainLossRelatedToLitigationSettlement_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBlankenshipMember_zfnfh2sDMWVa" title="Loss on settlement">419,900 for the year ended September 30, 2021. Concurrently with the severance agreement, the Company agreed to purchase the <span id="xdx_904_ecustom--PurchasePrice_pid_uShares_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBlankenshipMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zADN6GkZc8n7" title="Purchase price of stock">1,000,000 shares Series E Preferred Stock held by Ms. Blankenship for $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBlankenshipMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zwjqkwu89rok" title="Share based compensation">325,000 in cash. The Company reissued those Series E preferred Shares to the Company’s new CEO James Katzaroff. The Company recognized stock-based compensation of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JamesKatzaroffMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zqfMs1zPJdM" title="Share based compensation">325,000 related to this reissuance. During the year ended September 30, 2021, the Company issued <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertChicoskiMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zbPfC64mQ0u2" title="Issuance of common stock">5,000,000 shares of common stock to its CFO Robert Chicoski, with a fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertChicoskiMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_ziMbEpqqPZNi" title="Fair value">75,000 as a finders fee related to the Company’s license agreement. As of September 30, 2021, the Company owed $161,655 to officers of the Company for compensation.

379126

119655

28900

16500

12400

180000

35000000

0.009

The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an equal amount of options as those instruments that are issued. The exercise price of these additional options will be 110% of the price per equity equivalent. The total fair value of these option grants at issuance was $284,840. During the year ended September 30, 2022, the Company recognized $186,926 of stock-based compensation, related to outstanding stock options. At September 30, 2022, the Company had $97,914 of unrecognized expenses related to options. Additionally, Mr. Katzaroff will earn a fee related to an strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold. As of September 30, 2022, no amounts have been earned or paid.

38130

130000

8600000

447200

317200

2600000

102700

419900

1000000

325000

5000000

75000

161655

Note 5. Convertible Notes Payable and Advances Convertible notes payable consisted of the following at September 30, 2022 and 2021: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 70%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2022</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible note dated April 13, 2017 in the original principal amount of $20,000, no stated maturity date, bearing interest at 3% per year, convertible into common stock at a rate of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zo6ZvEey1Gb7" title="Conversion price">0.01 per share.</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_985_eus-gaap--ConvertibleDebt_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zNuixCrxuQr7" style="border-bottom: black 1pt solid; text-align: right" title="Convertible note">20,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_98A_eus-gaap--ConvertibleDebt_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zdcPvccUCvk9" style="border-bottom: black 1pt solid; text-align: right" title="Convertible note">20,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total current convertible notes payable, net of discount</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_982_eus-gaap--ConvertibleDebt_iI_c20220930_zt2kUh9EdQH4" style="border-bottom: black 2.25pt double; text-align: right">20,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20210930_zcMhI5UwEDha" style="border-bottom: black 2.25pt double; text-align: right">20,000</td> <td> </td></tr> </table> All principal along with accrued interest is payable on the maturity date. <span id="xdx_907_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20211001__20220930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z07CHPEMe382" title="Beneficial conversion discount on convertible note payable">The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.9% of the outstanding stock of the Company. During the year ended September 30, 2021, the Company recognized $10,000 of deferred finance costs from its new convertible note payable and $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20211001__20220930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zG9JO5roy0Df" title="Beneficial conversion discount on convertible note payable">225,000 of new discount related to the beneficial conversion features of convertible notes payable. During the year ended September 30, 2021, the Company recognized interest expense on convertible notes of $11,415 and amortization of discount on convertible notes payable of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20201001__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_ze8S2dQOvIBi" title="Beneficial conversion discount on convertible note payable">269,923, respectively. As of September 30, 2022 and September 30, 2021, accrued interest on convertible notes payable was $225,953 and $222,287, respectively. Conversions to Common Stock During the year ended September 30, 2021, the holders of the convertible notes payable elected to convert principal of $275,000 and accrued interest of $16,502 into 40,817,050 shares of common stock. There was no gain or loss recognized as the conversion occurred in accordance with the original terms of the agreement. Advances As of September 30, 2022 and 2021, the Company had non-interest bearing advances payable to third parties of $<span id="xdx_908_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20220930__us-gaap--ShortTermDebtTypeAxis__custom--AdvanceMember_zwRn1OcnOIv6" title="Accounts payable and accrued liabilities"><span id="xdx_90A_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--AdvanceMember_zHFgV7djTV9i" title="Accounts payable and accrued liabilities">59,650. These advances are payable on demand.

Convertible notes payable consisted of the following at September 30, 2022 and 2021: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 70%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2022</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2021</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible note dated April 13, 2017 in the original principal amount of $20,000, no stated maturity date, bearing interest at 3% per year, convertible into common stock at a rate of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zo6ZvEey1Gb7" title="Conversion price">0.01 per share.</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_985_eus-gaap--ConvertibleDebt_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zNuixCrxuQr7" style="border-bottom: black 1pt solid; text-align: right" title="Convertible note">20,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_98A_eus-gaap--ConvertibleDebt_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zdcPvccUCvk9" style="border-bottom: black 1pt solid; text-align: right" title="Convertible note">20,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total current convertible notes payable, net of discount</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_982_eus-gaap--ConvertibleDebt_iI_c20220930_zt2kUh9EdQH4" style="border-bottom: black 2.25pt double; text-align: right">20,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20210930_zcMhI5UwEDha" style="border-bottom: black 2.25pt double; text-align: right">20,000</td> <td> </td></tr> </table>

2017-04-13

20000

0.03

0.01

20000

The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.9% of the outstanding stock of the Company.

10000

225000

11415

269923

225953

222287

275000

16502

40817050

59650

Note 6. Stockholders’ deficit Preferred Stock Our authorized preferred stock consists of 20,000,000 shares of $0.001 par value preferred stock. Series A Preferred Stock – Our board of directors has designated up to <span id="xdx_902_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbCaV9a0lge6" title="Preferred stock, shares designated">6,000,000 shares of Series A Preferred Stock. The Series A Preferred Stock has a liquidation value of $<span id="xdx_900_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUyUeHqQCJe6" title="Preferred stock liquidation preference">2.00 per share. The initial number issued is 5,000,000 with additional shares to be issued as a dividend not to exceed a total of <span id="xdx_901_eus-gaap--PreferredStockDividendsShares_pid_uShares_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxw8bGTiHPre" title="Preferred stock dividends">6,000,000 shares. The rank of the Series A is prior to all common and preferred shares. In addition, the Series A Preferred Stock retains protective provisions to maintain their seniority with respect to liquidation or dissolution. The Series A Preferred Stock holds no voting rights and earns an <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOA7oumdmk6h" title="Preferred stock dividend rate">8% per annum dividend, payable in additional shares of Series A Preferred Stock. At September 30, 2022 and 2021, there were <span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNeHKcDmMEb6" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zmWIepBr6Db5" title="Preferred stock, shares outstanding">no shares of our Series A Preferred Stock outstanding, respectively. Series B Preferred Stock – Our board of directors has designated up to 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock has a liquidation value of $<span id="xdx_90B_eus-gaap--PreferredStockLiquidationPreference_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmkzJGo5XSxa" title="Preferred stock liquidation preference">1.00 per share. The holders of the Series B Preferred Stock are entitled to dividends of <span id="xdx_907_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJocsRPukl43" title="Preferred stock dividend rate">8% per year payable quarterly in cash or in shares of common stock at the option of the Company. The holders of the Series B Preferred Stock have no voting rights. The Series B Preferred Stock is redeemable at the option of the Company at a price of $1.00 per share. At September 30, 2022 and 2021, there were <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgGGGyFuF8l3" title="Preferred stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbMGGKVjI3bb" title="Preferred stock, shares outstanding">no shares of our Series B Preferred Stock outstanding. Series C Preferred Stock – On September 12, 2017, our board of directors designated up to <span id="xdx_900_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20170912__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqI1y3fj21Mh" title="Preferred stock, shares designated">1,200,000 shares of Series C Preferred Stock with a liquidation value of $<span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20170912__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7Zkg1PsJDRd" title="Preferred stock liquidation preference">0.50 per share. The holders of the Series C Preferred Stock have no voting rights. The Series C Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of one share of common stock for each share of Series C Preferred Stock. The Series C Preferred Stock is redeemable at the option of the Company at a price of $<span id="xdx_90E_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20170912__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zVcJncahvVi8" title="Preferred stock redemption price per share">0.50 per share. The Series C Preferred Stock has been canceled, and there are no shares of Series C Preferred Stock outstanding as of September 30, 2022 and 2021. Series D Preferred Stock – On September 21, 2017, our board of directors designated up to <span id="xdx_90A_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zlYb5wXisM62" title="Preferred stock, shares designated">539,988 shares of Series D Preferred Stock with a liquidation value of $<span id="xdx_901_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zDBlhG9k0u8e" title="Preferred stock liquidation preference">1.00 per share. The holders of the Series D Preferred Stock have no voting rights. <span id="xdx_90D_eus-gaap--PreferredStockConversionBasis_c20170920__20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zoaCcJK7cvQc" title="Preferred stock, conversion basis">The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series D Preferred Stock is not redeemable. At September 30, 2022 and 2021, there were 509,988 shares of Series D Preferred Stock outstanding. Series E Preferred Stock – On August 3, 2015, our board of directors designated 1,000,000 shares of Series E Preferred stock. The Series E Preferred stock is subordinate to our common stock. It does not receive dividends and does not participate in equity distributions. The Series E Preferred stock retained 2/3 of the voting rights in the Company. At September 30, 2022 and 2021, there were <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zILxtxdoDUx3" title="Preferred stock authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zgtFaROiqs0k" title="Preferred stock authorized">1,000,000 shares of Series E Preferred stock outstanding. Dividends, when, as and if declared by the Board of Directors, shall be paid out of funds at the time legally available for such purposes. Series F Preferred Stock – On September 21, 2017, our board of directors designated up to <span id="xdx_90F_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zTVE1dl3Hcqg" title="Preferred stock, shares designated">501,975 shares of Series F Preferred Stock with a liquidation value of $<span id="xdx_909_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zdl6YBw98i9b" title="Preferred stock liquidation preference">1.00 per share. The holders of the Series F Preferred Stock have no voting rights. <span id="xdx_90A_eus-gaap--PreferredStockConversionBasis_c20170920__20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zAWCnXVrghSa" title="Preferred stock, conversion basis">The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series F Preferred Stock is not redeemable. At September 30, 2021, 386,975 shares of the Series F Preferred Stock were issued and outstanding. During the year ended September 30, 2022, <span id="xdx_901_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zH3JMumQfHO3" title="Convertible preferred stock shares">257,984 shares of Series F Preferred Stock was converted into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zyf7kZBytktg" title="Conversion of shares converted">25,798,400 shares of common stock. At September 30, 2022, 128,991 shares of the Series F Preferred Stock were issued and outstanding. Conversions to Common Stock of Convertible Notes Payable During the year ended September 30, 2021, the holders of the convertible notes payable elected to convert principal and accrued interest of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20201001__20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_z0CcHNSfCHI6" title="Beneficial conversion discount on convertible note payable">291,500 into 40,817,050 shares of common stock. There was no gain or loss recognized as the conversion occurred in accordance with the original terms of the agreement. Common stock issued for services In March 2021, the Company entered into severance agreement with its former CEO Alex Blankenship. The Company owed Ms. Blankenship unpaid compensation of $130,000 and agreed to issue 8,600,000 shares of common stock in full settlement of this amount and release from the employment agreement with her. The shares had a fair value of $447,200 based on the stock price at the date of the agreement. The Company recognized a loss on settlement of $317,200 in connection with this agreement. The Company also issued an additional 2,600,000 shares to Ms. Blankenship with a fair value of $102,700 in connection with this agreement, which were included in the loss on settlement total of $419,900 for the year ended September 30, 2021. Concurrently with the severance agreement, the Company agreed to purchase the 1,000,000 shares Series E Preferred Stock held by Ms. Blankenship for $325,000 in cash. The Company reissued those Series E preferred Shares to the Company’s new CEO James Katzaroff. The Company recognized stock-based compensation of $325,000 related to this reissuance. During the year ended September 30, 2021, the Company issued a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20201001__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zAKzYLNLKnBe" title="Conversion of convertible securities">15,000,000 shares to three individuals for services rendered, including 5,000,000 to the Company’s CFO. The shares had a total fair value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20210930__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zKYsevoabF3j" title="Fair value">717,500 based on the stock price at the date the shares were earned, which was recognized as stock-based compensation. Common stock issued for settlement of liabilities During the year ended September 30, 2022, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20211001__20220930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zXnwd77TeCpb" title="Stock issued during period, shares, conversion of convertible securities">6,000,000 shares of common stock and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvgHkVwEx7Yg" title="Stock issued during period, shares, conversion of convertible securities">900,000 warrants for the settlement of liabilities totaling $<span id="xdx_90C_eus-gaap--GainLossRelatedToLitigationSettlement_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWQEaUjD6KF1" title="Gain (loss) related to litigation settlement">15,000. The Company recorded a $<span id="xdx_906_eus-gaap--GainLossRelatedToLitigationSettlement_c20211001__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zgWJliJnJpr6" title="Gain (loss) related to litigation settlement">146,460 loss on settlement of liabilities related to this transaction Common stock issued for stock payable In December 2021, the Company issue 19,980,000 shares of common stock as part of the common stock unit sales that occurred during the year ended September 30, 2021. As of September 30, 2022, no shares are remaining to be issued for these unit sales. In September 2022, the Company received $5,000 of cash as a subscription for 1,515,152 shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $0.01 for one year. The common shares were not yet issued as of September 30, 2022. Common Stock Units During the year ended September 30, 2021 the Company sold common stock units to investors. Each unit consist of 400,000 shares of common stock and 600,000 warrants to purchase common stock for three years at an exercise price of $0.03 per share. The Company received cash proceeds of $499,500 related to the issuance of 19,980,000 shares of common stock and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeOMIjHwj1Ce" title="Common stock issued for conversion of convertible note payable and accrued interest (in shares)">29,970,000 warrants. No shares of common stock were issued as of September 30, 2021. The shares were issued in December 2021. The warrants had a relative fair value of $350,462 based on a Black-Scholes pricing model with estimated volatility ranging from <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAQnJzMelnD5" title="Minimum volatility">261.3% to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zetkhnFC20Fg" title="Maximum volatility">261.8%, dividend yield of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYelriWQPdOa" title="Dividend yield">0%, expected term of three years and a risk free rate ranging from <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHle2Z5jPZ1a" title="Risk free rate, minimum">0.19% to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z25Ekkoihxc9" title="Risk free rate, maximum">0.24%. As of September 30, 2021, the warrants had no intrinsic value, and a weighted average remaining life of 2.4 years. Common Stock Warrants As discussed in Note 7 below, the Company awarded common stock warrants to a consultant. The Company recognized $322,266 of expense related to these warrants during the year ended September 30, 2022. The Company estimated the fair value of the warrants based on a Black-Scholes pricing model using the following assumptions: 1) volatility of 254.43%; 2) risk free rate of 1.76%; 3) dividend yield of 0% and 4) expected term of 5 years. The following table summarizes the stock warrant activity for the years ended September 30, 2022 and 2021: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price Per Share</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iS_pid_uShares_c20201001__20210930_znANTKF4kGdb" style="width: 13%; text-align: right" title="Warrants outstanding, beginning">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iS_pid_uShares_c20201001__20210930_zeuVKpG4aPpg" style="width: 13%; text-align: right" title="Warrants outstanding, beginning">—</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_989_ecustom--ShareBasedCompensationArrangementWarrantGrantedNumberone_pid_uShares_c20201001__20210930_zVzVZYSnkBNg" style="text-align: right" title="Granted">29,970,000</td> <td> </td> <td> </td> <td> </td> <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice_pid_uShares_c20201001__20210930_zjjWCOZmc5f4" style="text-align: right" title="Warrants outstanding, beginning">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding, September 30, 2021</td> <td> </td> <td> </td> <td id="xdx_985_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iS_pid_uShares_c20211001__20220930_z9idTX1AA2ed" style="text-align: right" title="Warrants outstanding, beginning">29,970,000</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iS_pid_uShares_c20211001__20220930_zppjkjsyaNSg" style="text-align: right" title="Warrants outstanding, beginning">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementWarrantGrantedNumberone_pid_uShares_c20211001__20220930_zcL9H8AIfPmi" style="text-align: right" title="Granted">41,415,152</td> <td> </td> <td> </td> <td> </td> <td id="xdx_988_ecustom--ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice_pid_uShares_c20211001__20220930_zdBtfKuCEUW2" style="text-align: right" title="Warrants outstanding, beginning">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding, September 30, 2022</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iE_pid_uShares_c20211001__20220930_zAgwXebGDeX6" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding, ending">71,385,152</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_989_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iE_pid_uShares_c20211001__20220930_zEnYHG41GGwb" style="text-align: right" title="Warrants outstanding, beginning">0.02</td> <td> </td></tr> </table> As of September 30, 2022, the outstanding warrants had an expected remaining life of<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zW7XOYcwDJK5" title="Expected life::XDX::P2Y11M26D"> 2.99 years and have no intrinsic value. Common Stock Options As discussed in Note 4, The Company awarded common stock options to Mr. Katzaroff in connection with his amended and restated employment agreement. The Company estimated the fair value of the options to be $284,840, using the following assumptions: 1) volatility of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20211001__20220930__srt--RangeAxis__srt--MinimumMember_zr1cfQfohWFb" title="Volatility rate">254.43%; 2) risk free rate of 1.54%; 3) dividend yield of 0% and 4) expected term of 3.38 years. The Company recognized $186,926 of expense related to the fair value of options vesting during the year ended September 30, 2022. The Company expects to recognize an additional $97,914 of expense related to these options assuming all vest. During the year ended September 30, 2021, the Board of Directors approved grants of 70,000,000 options to officers and medical advisory board members. The stock options have an exercise price of $0.03 per share and are exercisable through the latter of two years from the effective date or two years after certain liquidity events. The total fair value of these option grants at issuance was $4,209,179. All options vested immediately. The following table summarizes the stock option activity for the years ended September 30, 2022 and 2021: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 0.6pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options</td> <td style="padding-bottom: 0.6pt"> </td> <td style="padding-bottom: 0.6pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price Per Share</td> <td style="padding-bottom: 0.6pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20201001__20210930_zQ2ln2EOdf4i" style="width: 13%; text-align: right" title="Option outstanding, beginning">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20201001__20210930_zHdKLXF8yymc" style="width: 13%; text-align: right" title="Option outstanding, per shares, beginning">—</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20201001__20210930_zIncmG2tkydc" style="text-align: right" title="Granted">70,000,000</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20201001__20210930_zmku42KLkXk" style="text-align: right" title="Granted">0.003</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20201001__20210930_ztU2S6ZrzJId" style="text-align: right" title="Exercised">—</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20201001__20210930_zf3fenSk8QE3" style="text-align: right" title="Exercised">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20201001__20210930_zPK6PK0u8QL2" style="text-align: right" title="Forfeited">—</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20201001__20210930_zIuyOVkxYir9" style="text-align: right" title="Forfeited">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20201001__20210930_zWqPiAApwTel" style="border-bottom: Black 1pt solid; text-align: right" title="Expired">—</td> <td> </td> <td> </td> <td style="border-bottom: Black 1pt solid">$</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20201001__20210930_zywRDve8B5Q4" style="border-bottom: Black 1pt solid; text-align: right" title="Expired">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding, September 30, 2021</td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20211001__20220930_zIRdWQIw6pD4" style="text-align: right" title="Option outstanding, beginning">70,000,000</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20211001__20220930_zpSzygq3vXT8" style="text-align: right" title="Option outstanding, per shares, beginning">0.003</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20211001__20220930_zZyh3ll0jKT8" style="text-align: right" title="Granted">35,000,000</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20211001__20220930_zpdIU2UNGhU5" style="text-align: right" title="Granted">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20211001__20220930_zTbqcbdAGTvh" style="text-align: right" title="Exercised">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Forfeited</td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20211001__20220930_zpJh4KeWuhW5" style="text-align: right" title="Forfeited">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 0.6pt">Expired</td> <td style="padding-bottom: 0.6pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20211001__20220930_zw4iiJGGUvT6" style="border-bottom: black 1pt solid; text-align: right" title="Expired">—</td> <td style="padding-bottom: 0.6pt"> </td> <td style="padding-bottom: 0.6pt"> </td> <td>$</td> <td style="text-align: right">—</td> <td style="padding-bottom: 0.6pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.8pt">Outstanding, September 30, 2022</td> <td style="padding-bottom: 1.8pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20211001__20220930_zGoOwTm5H5v5" style="border-bottom: black 2.25pt double; text-align: right" title="Option outstanding, ending">105,000,000</td> <td style="padding-bottom: 1.8pt"> </td> <td style="padding-bottom: 1.8pt"> </td> <td>$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20211001__20220930_zQI7CMnTMVNh" style="text-align: right" title="Option outstanding, per shares, ending">0.02</td> <td style="padding-bottom: 1.8pt"> </td></tr> </table> As of September 30, 2022, the aggregate intrinsic value of options vested and outstanding were $0. As of September 30, 2022, all outstanding options had an expected remaining life of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxL_c20211001__20220930_zzaNaFQW4gBg" title="Expected remaining life::XDX::P1Y10M10D">1.86 years. Beneficial Conversion Feature During the year ended September 30, 2021, the Company charged to additional paid-in capital the aggregate amount of $225,000, in connection with the beneficial conversion feature of notes payable.

6000000

2.00

5000000

6000000

0.08

1000000

1.00

0.08

1200000

0.50

539988

1.00

The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock.

509988

1000000

The Series E Preferred stock retained 2/3 of the voting rights in the Company.

1000000

501975

1.00

The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock.

386975

257984

25798400

128991

291500

40817050

15000000

717500

6000000

900000

15000

146460

19980000

5000

400000

600000

0.03

499500

29970000

350462

2.613

2.618

0.0019

0.0024

As discussed in Note 7 below, the Company awarded common stock warrants to a consultant. The Company recognized $322,266 of expense related to these warrants during the year ended September 30, 2022. The Company estimated the fair value of the warrants based on a Black-Scholes pricing model using the following assumptions: 1) volatility of 254.43%; 2) risk free rate of 1.76%; 3) dividend yield of 0% and 4) expected term of 5 years. The following table summarizes the stock warrant activity for the years ended September 30, 2022 and 2021: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price Per Share</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iS_pid_uShares_c20201001__20210930_znANTKF4kGdb" style="width: 13%; text-align: right" title="Warrants outstanding, beginning">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iS_pid_uShares_c20201001__20210930_zeuVKpG4aPpg" style="width: 13%; text-align: right" title="Warrants outstanding, beginning">—</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_989_ecustom--ShareBasedCompensationArrangementWarrantGrantedNumberone_pid_uShares_c20201001__20210930_zVzVZYSnkBNg" style="text-align: right" title="Granted">29,970,000</td> <td> </td> <td> </td> <td> </td> <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice_pid_uShares_c20201001__20210930_zjjWCOZmc5f4" style="text-align: right" title="Warrants outstanding, beginning">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding, September 30, 2021</td> <td> </td> <td> </td> <td id="xdx_985_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iS_pid_uShares_c20211001__20220930_z9idTX1AA2ed" style="text-align: right" title="Warrants outstanding, beginning">29,970,000</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iS_pid_uShares_c20211001__20220930_zppjkjsyaNSg" style="text-align: right" title="Warrants outstanding, beginning">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementWarrantGrantedNumberone_pid_uShares_c20211001__20220930_zcL9H8AIfPmi" style="text-align: right" title="Granted">41,415,152</td> <td> </td> <td> </td> <td> </td> <td id="xdx_988_ecustom--ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice_pid_uShares_c20211001__20220930_zdBtfKuCEUW2" style="text-align: right" title="Warrants outstanding, beginning">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding, September 30, 2022</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iE_pid_uShares_c20211001__20220930_zAgwXebGDeX6" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding, ending">71,385,152</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_989_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iE_pid_uShares_c20211001__20220930_zEnYHG41GGwb" style="text-align: right" title="Warrants outstanding, beginning">0.02</td> <td> </td></tr> </table>

322266

29970000 0.03 29970000 0.03 41415152 0.01 71385152 0.02

2.5443

1.54

186926

97914

The following table summarizes the stock option activity for the years ended September 30, 2022 and 2021: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 0.6pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options</td> <td style="padding-bottom: 0.6pt"> </td> <td style="padding-bottom: 0.6pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price Per Share</td> <td style="padding-bottom: 0.6pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20201001__20210930_zQ2ln2EOdf4i" style="width: 13%; text-align: right" title="Option outstanding, beginning">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20201001__20210930_zHdKLXF8yymc" style="width: 13%; text-align: right" title="Option outstanding, per shares, beginning">—</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20201001__20210930_zIncmG2tkydc" style="text-align: right" title="Granted">70,000,000</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20201001__20210930_zmku42KLkXk" style="text-align: right" title="Granted">0.003</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20201001__20210930_ztU2S6ZrzJId" style="text-align: right" title="Exercised">—</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20201001__20210930_zf3fenSk8QE3" style="text-align: right" title="Exercised">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20201001__20210930_zPK6PK0u8QL2" style="text-align: right" title="Forfeited">—</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20201001__20210930_zIuyOVkxYir9" style="text-align: right" title="Forfeited">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20201001__20210930_zWqPiAApwTel" style="border-bottom: Black 1pt solid; text-align: right" title="Expired">—</td> <td> </td> <td> </td> <td style="border-bottom: Black 1pt solid">$</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20201001__20210930_zywRDve8B5Q4" style="border-bottom: Black 1pt solid; text-align: right" title="Expired">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding, September 30, 2021</td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20211001__20220930_zIRdWQIw6pD4" style="text-align: right" title="Option outstanding, beginning">70,000,000</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20211001__20220930_zpSzygq3vXT8" style="text-align: right" title="Option outstanding, per shares, beginning">0.003</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20211001__20220930_zZyh3ll0jKT8" style="text-align: right" title="Granted">35,000,000</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20211001__20220930_zpdIU2UNGhU5" style="text-align: right" title="Granted">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20211001__20220930_zTbqcbdAGTvh" style="text-align: right" title="Exercised">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Forfeited</td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20211001__20220930_zpJh4KeWuhW5" style="text-align: right" title="Forfeited">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 0.6pt">Expired</td> <td style="padding-bottom: 0.6pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20211001__20220930_zw4iiJGGUvT6" style="border-bottom: black 1pt solid; text-align: right" title="Expired">—</td> <td style="padding-bottom: 0.6pt"> </td> <td style="padding-bottom: 0.6pt"> </td> <td>$</td> <td style="text-align: right">—</td> <td style="padding-bottom: 0.6pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.8pt">Outstanding, September 30, 2022</td> <td style="padding-bottom: 1.8pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20211001__20220930_zGoOwTm5H5v5" style="border-bottom: black 2.25pt double; text-align: right" title="Option outstanding, ending">105,000,000</td> <td style="padding-bottom: 1.8pt"> </td> <td style="padding-bottom: 1.8pt"> </td> <td>$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20211001__20220930_zQI7CMnTMVNh" style="text-align: right" title="Option outstanding, per shares, ending">0.02</td> <td style="padding-bottom: 1.8pt"> </td></tr> </table>

70000000

0.003

70000000

0.003

35000000

0.01

105000000

0.02

225000

Note 7. Series G Preferred Stock On August 11, 2021, our board of directors designated up to <span id="xdx_90B_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zjwJmbFjND5l" title="Preferred stock, shares designated">1,000,000 shares of Series G Preferred Stock with a liquidation value of $<span id="xdx_90D_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zAjQll7vQY2e" title="Preferred stock liquidation preference">1.00 per share. The holders of the Series G Preferred Stock have no voting rights except on matters related specifically to the Series G Preferred Stock. <span id="xdx_902_eus-gaap--PreferredStockConversionBasis_c20210809__20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zTN4J506Wwt8" title="Preferred stock, conversion basis">The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default. The Series G Preferred Stock and accrued dividends are convertible beginning 180 days from issuance at the option of the holder into shares of common stock at a rate of a conversion price of 75% of the average three lowest trading prices during the 15 days prior to conversion. The Company will be required to redeem the Series G Preferred Stock upon the earlier of 15 months from issuance date or upon on event of default as defined in the agreement. The Company sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_uShares_c20210809__20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zkQqnI28vpol" title="Number of share sold">93,500 shares for net cash proceeds of $81,250 of cash proceeds. Based on the economic characteristics of the Series G Preferred Stock, the Company determined that the Series G should be accounted for as a liability under ASC 480-10, based on the discounted conversion price providing an effectively fixed monetary amount that the preferred stock is convertible into. The Company recorded a debt discount of $25,000 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $106,250. The Company amortized $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z9AOz8V7tvK2" title="Amortization of debt discount">2,425 of this discount through September 30, 2021. The dividends on the Series G Preferred Stock are recorded as interest expense and totaled $1,164 through September 30, 2021. During the year ended September 30, 2022, the Company sold an aggregate of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_uShares_c20210810__20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zO55A0NhQce1" title="Number of share sold">369,875 shares of Series G Preferred Stock for net cash proceeds of $310,000. The Company recorded a debt discount of $59,875 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $369,875. The Company amortized $54,664 of discount related to Series G Preferred Stock for the year months ended September 30, 2022. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $15,852 of interest on the Series G Preferred Stock and had an accrued interest balance of $3,983 and $1,281 as of September 30, 2022 and September 30, 2021, respectively. During the year ended September 30, 2022, the holder of the Series G converted <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z4zF1hgPE9oj" title="Conversion of stock shares converted">324,500 shares of Series G and $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueStockDividend_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDUfCwNbpyw4" title="Dividend value">12,980 of dividends into <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLXhsRRZsxG4" title="Conversion of stock shares converted">109,052,543 shares of common stock, and the Company recognized a loss of $5,939. As of September 30, 2022 and September 30, 2021, <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zbQ5em8bS9Lk" title="Preferred stock, shares outstanding">138,875 and <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pid_uShares_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zlKLdJ4KWnub" title="Preferred stock, shares outstanding">93,500 shares of the Series G Preferred Stock were issued and outstanding, respectively. The balance of the Series G Preferred stock liability was $126,294 and $86,130, respectively, net of unamortized discount of $12,581 and $30,745, respectively. 1000000

1.00

The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default.

93500

81250

25000

106250

2425

1164

369875

310000

59875

369875

54664

3983

1281

324500

12980

109052543

5939

138875

93500

12581

30745

Note 8. Commitments and Contingent Liabilities In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the “Consultant”). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company fir a period of five years unless mutually terminated sooner. Concurrently, the Consultant entered into a stock purchase agreement with the Company to purchase 6,000,000 shares of common stock for $25,000 cash. The purchase and issuance of the shares was to be completed by June 30, 2022 but has not yet occurred. The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock. The Consultant may also receive a bonus in each calendar year of the agreement equal to the larger of any bonus awarded by the Board of Directors to the Consultant or 50% of the largest bonus payable by the Company to anyone other than the Consultant. If the agreement is terminated with one year of a change of control of the Company, the Consultant will be entitled to receive a payment equal to 2.99 times the larger of the total compensation paid to the Consultant over the prior 12 month period or the average compensation paid or payable to the Consultant over the prior three years. The Consultant also received 39,000,000 warrants with an exercise price of $0.009 per share, and an exercise period of 5 years. The Company estimated the fair value of the warrants to be $322,266 which was recognized as general and administrative expense during the nine months ended June 30, 2022, using the following assumptions: 1) volatility of <span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingMeasurementInput1_iI_pid_dp_uPure_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zDxytS4ZGyQ6" title="Assumption rate">254.4%; 2) risk free rate of <span id="xdx_900_ecustom--WarrantsAndRightsOutstandingMeasurementInput2_iI_pid_dp_uPure_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zAQJ49iZXlpc" title="Assumption rate">1.76%; 3) dividend yield of <span id="xdx_903_ecustom--WarrantsAndRightsOutstandingMeasurementInput3_iI_pid_dp_uPure_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementDividendYieldRateMember_z68X8kfidOU7" title="Assumption rate">0% and 4) expected term of 5 years. The Consultant is also entitled to additional warrants in the event of the Company issuing equity or equity equivalents in the future, with the Consultant receiving an equal amount of warrants as those instruments that are issued. The exercise price of these additional warrants will be 110% of the price per equity equivalent, and they will vest 50% immediately and the remainder over two years. Litigation From time to time, the Company may be subject to routine litigation, claims, or disputes in the ordinary course of business. In the opinion of management, no pending or known threatened claims, actions or proceedings against the Company are expected to have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company cannot predict with certainty, however, the outcome or effect of any of the litigation or investigatory matters specifically described above or any other pending litigation or claims. There can be no assurance as to the ultimate outcome of any lawsuits and investigations.

6000000

25000

The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock

39000000

0.009

322266

2.544 0.0176 0

The exercise price of these additional warrants will be 110% of the price per equity equivalent, and they will vest 50% immediately and the remainder over two years

Note 9. License Agreement Effective August 23, 2020 the Company’s wholly-owned subsidiary, SomaCeuticals, Inc. entered into an exclusive global license agreement with 7 to Stand, Inc. for the rights to U.S. patent <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200822__20200823__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FabrizioDeSilvestriMember_zIr3KZtFLOg3" title="Rights to issued">10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis. In consideration for the license agreement, SomaCeuticals agreed to pay 7 to Stand a royalty of <span id="xdx_908_ecustom--RoyaltyOfNetSalesPercentage_pid_dp_uPure_c20200822__20200823__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zZXAlfjlVLe2" title="Royalty of net sales">7.1% of the net sales of any product developed under the patent on a worldwide basis. Additionally, the Company will issue shares of common stock to 7 to Stand upon completion of the following milestones: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 6%">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 94%">Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.</td></tr> </table> The Company paid $52,000 in royalties during the year ended September 30, 2022 and owes $26,250 of royalties and late fees under this agreement as of September 30, 2022. During the year ended September 30, 2021, the Company recognized share-based compensation expense of $3,204,318 related to the 58,260,334 shares issued pursuant to the first two milestones described above, based on the closing price of the Company’s common stock on the date the milestone was met. The Company is currently in default of this agreement.

10610592

0.071 Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021. 29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021. 29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met. $40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.

52000

26250

3204318

58260334

Note 10. Income Taxes There is no current or deferred income tax expense or benefit for the period ended September 30, 2022 and 2021. The Company currently has net operating loss carryforwards aggregating approximately $4,571,000 which expire beginning in 2033. The deferred tax asset related to the net operating loss carryforwards has been fully reserved. The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference for the period from April 29, 2016 (date of inception) through September 30, 2022 and 2021 is the valuation allowance as follows. Schedule of provision for income taxes <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" id="xdx_49C_20211001__20220930_zhzKDQOtjWe7" style="border-bottom: black 1pt solid; text-align: center">September 30, 2022</td> <td> </td> <td colspan="2" id="xdx_49E_20201001__20210930_zIvJhFRVkcxa" style="border-bottom: black 1pt solid; text-align: center">September 30, 2021</td> <td> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzhSZ_zkgEKgkpNts4" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%">Net operating loss carryforward at statutory tax rate</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">962,000</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">768,000</td> <td style="width: 1%"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzhSZ_zKpkiNLKONP3" style="vertical-align: bottom; background-color: white"> <td style="text-indent: 6.5pt">Valuation allowance</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(962,000</td> <td style="padding-bottom: 0.5pt">)</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(768,000</td> <td style="padding-bottom: 0.5pt">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzhSZ_zZvr59SpKlU7" style="vertical-align: bottom; background-color: #CCEEFF"> <td>Deferred tax benefit, net</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> </table> The Company has not recognized an income tax benefit for the period based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the current period presented is offset by a valuation allowance (100%) established against deferred tax assets arising from operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. The tax returns for fiscal year 2017 and forward are still open for review by the Internal Revenue Service.

4571000

The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference for the period from April 29, 2016 (date of inception) through September 30, 2022 and 2021 is the valuation allowance as follows. Schedule of provision for income taxes <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" id="xdx_49C_20211001__20220930_zhzKDQOtjWe7" style="border-bottom: black 1pt solid; text-align: center">September 30, 2022</td> <td> </td> <td colspan="2" id="xdx_49E_20201001__20210930_zIvJhFRVkcxa" style="border-bottom: black 1pt solid; text-align: center">September 30, 2021</td> <td> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzhSZ_zkgEKgkpNts4" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%">Net operating loss carryforward at statutory tax rate</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">962,000</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">768,000</td> <td style="width: 1%"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzhSZ_zKpkiNLKONP3" style="vertical-align: bottom; background-color: white"> <td style="text-indent: 6.5pt">Valuation allowance</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(962,000</td> <td style="padding-bottom: 0.5pt">)</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(768,000</td> <td style="padding-bottom: 0.5pt">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzhSZ_zZvr59SpKlU7" style="vertical-align: bottom; background-color: #CCEEFF"> <td>Deferred tax benefit, net</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> </table>

962000

768000

-962000

-768000

Note 11. Subsequent Events On October 3, 2022, the holders of the Series G Preferred Stock converted a total of <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20221002__20221003__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5hBBW5zcQ5c" title="Number of shares converted in a noncash (or part noncash) transaction">15,000 shares and dividends of $<span id="xdx_900_eus-gaap--DividendIncomeOperating_c20221002__20221003__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOVLLdwB1z6" title="Dividend income operating">600 into <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_uShares_c20221002__20221003__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHEoCa4kvavk" title="Number of shares issued in exchange for the original debt">7,090,909 shares of common stock. On October 13, 2022, the holders of the Series G Preferred Stock converted a total of <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20221012__20221013__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIhLu8Zw1IZ" title="Number of shares converted in a noncash (or part noncash) transaction">15,000 shares and dividends of $<span id="xdx_909_eus-gaap--DividendIncomeOperating_c20221012__20221013__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWyj9IJuxgN">600 into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_uShares_c20221012__20221013__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHUqTfbh6Pyb" title="Number of shares issued in exchange for the original debt">7,090,909 shares of common stock. On October 18, 2022, the holders of the Series G Preferred Stock converted a total of <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20221017__20221018__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDwIfWyCQXNk" title="Number of shares converted in a noncash (or part noncash) transaction">18,125 shares and dividends of $<span id="xdx_908_eus-gaap--DividendIncomeOperating_c20221017__20221018__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFehwq2XLcxj">725 into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_uShares_c20221017__20221018__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zL0oXbl3vw1c" title="Number of shares issued in exchange for the original debt">8,976,190 shares of common stock. On November 10, 2022, the holders of the Series G Preferred Stock converted a total of <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20221109__20221110__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVmYOts4OXAl" title="Number of shares converted in a noncash (or part noncash) transaction">20,000 shares and dividends of $<span id="xdx_907_eus-gaap--DividendIncomeOperating_c20221109__20221110__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbO1qFf3pMEb">800 into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_uShares_c20221109__20221110__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMiyQsT2xhxc" title="Number of shares issued in exchange for the original debt">10,947,368 shares of common stock. On November 14, 2022, the holders of the Series G Preferred Stock converted a total of <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20221113__20221114__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZOaJlSATId2" title="Number of shares converted in a noncash (or part noncash) transaction">28,125 shares and dividends of $<span id="xdx_90B_eus-gaap--DividendIncomeOperating_c20221113__20221114__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvvDl2GSUCQd">1,125 into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_uShares_c20221113__20221114__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFXk27AToUPi" title="Number of shares issued in exchange for the original debt">13,928,571 shares of common stock.

15000

600

7090909

15000

600

7090909

18125

725

8976190

20000

800

10947368

28125

1125

13928571